Jason Ryan the Chief Financial Officer of Foundation Medicine, Inc. (FMI) Sold 2,336 Shares of the Company; Tengasco (NYSEAMERICAN:TGC) Shorts Down By 58.61%

January 4, 2018 - By Martha Paddon

Tengasco Incorporated (NYSEAMERICAN:TGC) had a decrease of 58.61% in short interest. TGC’s SI was 40,400 shares in January as released by FINRA. Its down 58.61% from 97,600 shares previously. With 88,400 avg volume, 1 days are for Tengasco Incorporated (NYSEAMERICAN:TGC)’s short sellers to cover TGC’s short positions. The SI to Tengasco Incorporated’s float is 0.83%. The stock decreased 0.67% or $0.01 during the last trading session, reaching $0.87. About 122,450 shares traded. Tengasco, Inc. (NYSEAMERICAN:TGC) has declined 31.06% since January 4, 2017 and is downtrending. It has underperformed by 47.76% the S&P500.

Jason Ryan, Chief Financial Officer of Foundation Medicine Inc is the insider, our company want to report transactions for. Mr. Jason submitted an electronic document with the U.S. SEC revealing a deal for 2,336 shares of the corporation, the one he is an insider in. At the time of the legal trading transaction, the average market stock price of Foundation Medicine Inc was $64.0, making the dealing worth $149,504 USD. He also sold 21,726 shares with a total value of about $1,330,935 USD in the last 30 days. Currently, Mr. Jason, owns 50,265 shares, which accounts for 0.14% of the company’s market cap. The insider’s activity definitely generated quite an interest in the stock community.

Tengasco, Inc., together with its subsidiaries, explores for and produces oil and natural gas in the United States. The company has market cap of $9.28 million. It primarily holds interests in the gas and oil properties located in Kansas. It currently has negative earnings. As of December 31, 2016, the firm had 177 producing oil wells, 23 shut-in wells, and 38 active disposal wells.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has market cap of $2.40 billion. The companyÂ’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patientÂ’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It currently has negative earnings. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer.

Investors sentiment decreased to 1.28 in 2017 Q3. Its down 0.51, from 1.79 in 2017Q2. It dropped, as 11 investors sold Foundation Medicine, Inc. shares while 18 reduced holdings. 7 funds opened positions while 30 raised stakes. 9.71 million shares or 0.07% less from 9.72 million shares in 2017Q2 were reported. Needham Inv Mngmt Ltd Co has invested 0.59% in Foundation Medicine, Inc. (NASDAQ:FMI). Germany-based Dekabank Deutsche Girozentrale has invested 0.01% in Foundation Medicine, Inc. (NASDAQ:FMI). Tower Cap (Trc) stated it has 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Amp Cap Investors holds 5,550 shares. Legal General Grp Public Ltd reported 3,815 shares or 0% of all its holdings. 1,748 were reported by Whittier Trust Co Of Nevada. Macquarie Grp Inc Ltd invested 0.01% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Renaissance Technology Ltd Liability Co reported 19,000 shares. Us National Bank & Trust De owns 400 shares or 0% of their US portfolio. Winslow Evans & Crocker holds 0% or 40 shares. Goldman Sachs Grp Incorporated stated it has 37,177 shares. Parallax Volatility Advisers Ltd Partnership holds 0% or 6,106 shares. Ipswich Invest Management Communications invested in 14,450 shares. Advisory Service Networks Llc holds 60 shares or 0% of its portfolio. Credit Suisse Ag stated it has 20,139 shares.

Among 9 analysts covering Foundation Medicine (NASDAQ:FMI), 1 have Buy rating, 0 Sell and 8 Hold. Therefore 11% are positive. Foundation Medicine has $30 highest and $19 lowest target. $24.33’s average target is -62.97% below currents $65.7 stock price. Foundation Medicine had 12 analyst reports since July 30, 2015 according to SRatingsIntel. On Tuesday, March 7 the stock rating was upgraded by Janney Capital to “Neutral”. BTIG Research upgraded the stock to “Buy” rating in Monday, May 15 report. The rating was downgraded by Benchmark on Thursday, November 3 to “Hold”. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Market Perform” rating by Wells Fargo on Wednesday, September 16. The stock has “Neutral” rating by BTIG Research on Wednesday, November 4. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) has “Neutral” rating given on Wednesday, September 21 by UBS. BTIG Research initiated the stock with “Buy” rating in Monday, September 14 report. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) earned “Market Perform” rating by JMP Securities on Thursday, July 30.

Since August 4, 2017, it had 0 insider purchases, and 14 insider sales for $8.02 million activity. $211,072 worth of Foundation Medicine, Inc. (NASDAQ:FMI) was sold by Nallicheri Melanie on Monday, October 2. The insider Kafka Steven J. sold $149,968. Shares for $1.85 million were sold by Daly David. The insider Pellini Michael J sold 4,349 shares worth $168,741. 2,165 shares valued at $84,002 were sold by Hesslein Robert W. on Monday, October 2. Yeshwant Krishna also sold $665,953 worth of Foundation Medicine, Inc. (NASDAQ:FMI) shares. Ryan Jason sold 3,154 shares worth $122,375.

Analysts await Foundation Medicine, Inc. (NASDAQ:FMI) to report earnings on February, 28. They expect $-1.00 EPS, up 1.96% or $0.02 from last year’s $-1.02 per share. After $-0.90 actual EPS reported by Foundation Medicine, Inc. for the previous quarter, Wall Street now forecasts 11.11% negative EPS growth.